Form 4: Krystal Biotech Executive Suma Krishnan Sells Shares Under 10b5-1 Trading Plan

Suma Krishnan, a Director and Officer at Krystal Biotech, sold shares of common stock on June 11, 2024, under a pre-existing 10b5-1 trading plan.

Summary

• Suma Krishnan, President of R&D and a Director at Krystal Biotech, sold shares of the company's common stock on June 11, 2024.
• The sales were executed under a Rule 10b5-1 trading plan that was adopted on September 11, 2023.
• The trading plan contemplated quarterly sales of 25,000 shares with a limit price of $100.00 per share.
• The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated.
• Krishnan sold a total of 25,000 shares directly at prices ranging from $171.3962 to $178.1447.
• Krishnan's spouse, Krish S. Krishnan, also sold shares under a separate 10b5-1 trading plan.
• Krish S. Krishnan sold a total of 25,000 shares directly at prices ranging from $171.488 to $178.3564.
• Following the transactions, Suma Krishnan directly owns 1,525,882 shares of Krystal Biotech common stock and indirectly owns 1,767,262 shares.
• Krish S. Krishnan directly owns 1,587,262 shares of Krystal Biotech common stock, and also indirectly owns 90,000 shares via the SMK Trust and 50,000 shares via the Krishnan Family Trust.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating insider transactions. The sentiment is neutral as it simply reports facts without expressing any opinion or forward-looking statements. The sales were conducted under a pre-arranged plan, mitigating potential negative interpretations.

Industry Context

Insider selling can sometimes be interpreted negatively by the market, but sales under pre-arranged 10b5-1 trading plans are generally viewed as less concerning since they are planned in advance to avoid accusations of trading on inside information.

Stakeholder Impact

• The sale of shares by a company insider could potentially create uncertainty among shareholders.
• However, the fact that the sales were executed under a pre-arranged 10b5-1 trading plan may mitigate any negative impact.

Key Dates